Navigation Links
Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting

-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanism of Action and In Vitro Compatibility with other HCV Inhibitors-

NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. today announced the presentation of data validating the clinical antiviral activity of one of Achillion's NS4A antagonists, ACH-806, for the treatment of hepatitis C virus (HCV) infection at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). In three separate presentations, Achillion researchers discussed the potent antiviral activity in HCV-infected subjects, synergy with other classes of HCV inhibitors, and the unique mode of action of a NS4A antagonist. Achillion has shown that blocking NS4A, a viral protein that binds to a portion of HCV protease, inhibits HCV replication. This program is part of a collaboration and exclusive license agreement with Gilead Sciences for the research, development and commercialization of compounds for the treatment of chronic HCV.

In a late-breaker session on April 14th at 5:00 PM, John Pottage, M.D., Senior Vice President and Chief Medical Officer at Achillion, discussed clinical data in a presentation titled, "Short-term Antiviral Activity and Safety of ACH-806 (GS-9132), an NS4A Antagonist, in HCV Genotype 1 Infected Individuals." The randomized, double-blind, placebo-controlled dose-escalation trial measured the antiviral activity, safety and pharmacokinetics of 300 mg of ACH-806 or placebo, dosed orally twice daily as a monotherapy over 5 days. The mean change in HCV RNA (log10) at day 5 was a decrease of 0.91 from baseline for treated subjects versus an increase of 0.05 for control subjects. Elevations in serum creatinine (a marker of kidney function) were observed in ACH-806 treated subjects and were reversible after completion of dosing.

"This study provides the first demonstration of human antiviral a
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014  Neurocrine ... that the Company will report its second quarter 2014 ... August 6, 2014.  Neurocrine will then host a live ... and provide a Company update Thursday morning, August 7, ... Time). Participants can access the live conference ...
(Date:7/29/2014)... TORONTO , July 29, ... ESAQ), an emerging pharmaceutical company exploring drug ... novel formulations and alternative dosage forms of ... its pharmaceutical development implementing its sub-micron platform technology.  ... drugs that will address indications in diabetes ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3
(Date:7/29/2014)... 2014 The Law Offices of Michael Cordova ... Hope, a non-profit organization providing grief camps for kids, teens, ... and suffering our clients experience from the death of a ... an organization like Stepping Stones of Hope, as they provide ... Stones of Hope also includes a monthly support group and ...
(Date:7/29/2014)... record the severity and regularity of their pain is ... , A new approach to the treatment of headaches, ... and is being led by Professor Paul Martin from ... He has developed an approach designed to enable people ... Learning to Cope with Triggers (LCT). , Using a ...
(Date:7/29/2014)... of cancer is to surgically remove the tumor. The ... surgeon may fail to extract the entire tumor, leading ... researchers at the University of Pennsylvania have established a ... in the patient, increasing the likelihood of a positive ... accumulates in cancerous tissues much more so than normal ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 A new ... during the 2014 Society for Cardiovascular Angiography and Interventions ... released this week. The videos review the benefits of ... services for the cardiac catheterization laboratory from the perspective ... the first video, Jane Kiah, MS, RN, Director of ...
(Date:7/29/2014)... boys with fragile X syndrome tend to decline ... of the inherited disorder to date has found. ... social and practical skills, including communication, socialization, and ... dressed. In this study, socialization emerged as a ... that it did not decline as much as ...
Breaking Medicine News(10 mins):Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 3Health News:Socialization relative strength in fragile X longitudinal study 2
... up with a remarkable discovery. Scientists there, have found ... have added benefits. Sildenafil and other drugs that help to ... chemical messenger seem to help in unveiling cancer cells. ... by that the immune system. , The ...
... Dr. Reddy's Laboratories will launch a first-of-its-kind pill to ... it was announced Thursday. // ,The company ... New Zealand, for trials of the groundbreaking 'polypill' that ... to treat heart ailments. , ,India records nearly ...
... multi vitamin supplements have a healthier diet and lifestyle ... ,Researchers led by Lindsay Reaves of the University of ... weight, diet and health behaviour of over 2,500 US ... , ,The study, which appeared in the December ...
... areas as part of a government plan to reach healthcare ... government has released initial funds to the tune of Rs. ... in rural areas. ,According to a health ministry ... Health Mission (NRHM) scheme for 2006-07. ,The ...
... is admissible to Orthopaedically Handicapped/Paraplegic persons, Completely Blind, ... (both afflictions together in the same person). Except ... all classes to other categories. Deaf & Dumb ... and First Class. Concession is granted in all ...
... The American Dental association announced on the 9th of November, ... preparation of infant formulation. // ,The dentists are concerned ... might be disastrous as instead of protecting teeth it might ... lead to weakened bones and even bone cancer boys. ...
Cached Medicine News:Health News:Impotency Drugs Help to Unmask Cancer Cells 2Health News:Dr. Reddy's To Launch 'Polypill' For Treating Heart Disease 2
... The Hancock® II bioprosthesis from ... years of proven clinical experience. ... the freedom from structural valve ... and mitral bioprostheses is substantially ...
... bioprosthesis from Medtronic has more ... clinical experience. Worldwide clinical studies ... structural valve deterioration with Hancock® ... is substantially better than results ...
Attain Venogram Balloon Catheter....
... cardioverter defibrillators (ICDs) are designed to treat ... (SCD) due to arrhythmia. The size and ... is designed to facilitate ease of insertion ... 2 system incorporates Guidant's proprietary RHYTHM ID ...
Medicine Products: